GlassScriptPhysician profile
Mina Kerolos
NPI 1013264936
$2,237.51
in general payments reported to CMS, 2019-2025
19 companies · $834 in 2025
The $834 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $474 · 2024: $929 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.08 |
| Education | $111.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $394.74 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $364.25 | 2023-2025 | |
| Boston Scientific Corporation | $279.92 | 2023-2025 | Avvigo Guidance System, Stingray, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.31 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $207.04 | 2024-2025 | Camzyos, Eliquis |
| Abiomed | $169.91 | 2024 | Impella |
| Edwards Lifesciences Corporation | $76.45 | 2024 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $68.47 | 2025 | Vitalflow Console |
| Actelion Pharmaceuticals US, INC. | $67.80 | 2024 | Uptravi |
| Janssen Pharmaceuticals, INC | $60.47 | 2024-2025 | Uptravi, Xarelto |
| Angiodynamics, INC. | $58.39 | 2024-2025 | Alphavac |
| Lantheus Medical Imaging, INC. | $50.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.58 | 2025 | |
| Ethicon US, LLC | $39.47 | 2024 | Monocryl, Stratafix |
| Alnylam Pharmaceuticals INC. | $38.01 | 2025 | Onpattro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.37 | 2025 | |
| Cvrx, INC. | $27.12 | 2025 | Barostim Neo System |
| Amgen INC. | $19.65 | 2023 | Repatha |
| Biosense Webster, INC. | $15.59 | 2023 | Na, Soundstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Kerolos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.